Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
CBD Nutraceuticals Market Size & Share 2026-2035
Report ID: GMI13355
|
Published Date: March 2025
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
CBD Nutraceuticals Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
CBD Nutraceuticals Market Size
The CBD nutraceuticals market was valued at USD 12.45 billion in 2025, advanced to USD 14.82 billion in 2026, is projected to grow at 17.3% CAGR (2026–2035), and is expected to reach USD 61.46 billion by 2035. The market covers hemp-derived CBD dietary and health-support products, including oils, tinctures, capsules, softgels, and gummies, sold through regulated retail, pharmacy, and online channels.
CBD Nutraceuticals Market Key Takeaways
Market Leader: Green Roads led with over 0.47% market share in 2025.
Leading Players: Top 5 players in this market include Green Roads, Charlotte's Web, Garden of Life (Nestlé), MEDTERRA, CV Sciences, which collectively held a market share of 1.45% in 2025.
The CBD nutraceuticals market is moving from an early wellness-led category toward a more differentiated supplement market shaped by repeat use, format accessibility, and regulatory compliance. Chronic-condition management supports recurring demand, while standardized dosing formats and clearer quality signals are broadening adoption among consumers who previously viewed CBD as a specialist product.
GMI Analyst View
Based on our ongoing analysis and cross-verification of market activity data, the global CBD nutraceuticals market registered a value of USD 10.70 billion in 2024. We view that established base as evidence that category demand is being sustained by recurring health and wellness use cases rather than by short-lived consumer experimentation.
CBD Nutraceuticals Market Trends, Growth Drivers & GMI Forecast Outlook
CBD nutraceutical demand is increasingly determined by whether brands can translate consumer interest in pain, stress, sleep, and broader wellness support into compliant, understandable products. Growth is strongest where accessible formats, trusted distribution, and workable regulatory pathways reinforce one another.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Chronic musculoskeletal conditions create an unusually durable demand environment because consumers often manage recurring discomfort over extended periods. Within CBD nutraceuticals, pain-oriented products compete less on pharmaceutical substitution and more on convenience, familiarity, and fit with self-directed wellness routines. Oils, capsules, and softgels can therefore support repeat purchasing when dosing confidence and product quality are evident.
Anxiety and stress applications rely on a different pathway to adoption. Consumers evaluating products for emotional wellness frequently require a credible use rationale, discreet formats, and reassurance that the product can be incorporated into an existing supplement regimen. Brands that pair accessible delivery formats with disciplined communication are better placed to convert first-time users and retain consumers seeking everyday stress-management support.
Regulatory clarity matters because it changes how manufacturers, retailers, pharmacists, and investors assess category risk. As compliance expectations become more actionable, brands can invest more confidently in labeling, education, quality systems, and channel partnerships. This favors operators able to demonstrate formulation consistency and responsible consumer guidance.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Extraction economics affect more than manufacturing cost. They influence an operator's ability to maintain batch consistency, finance quality controls, and supply standardized formulations across multiple sales channels. Smaller brands that rely on external processors may preserve capital, but they often face less control over specifications, procurement timing, and margin structure. That imbalance can slow portfolio expansion in products requiring tightly managed dosing and compliance documentation.
European constraints operate primarily through formulation and authorization risk. When permitted exposure levels, novel-food requirements, and national rules do not align, brands must make product, labeling, and distribution decisions market by market. The resulting friction favors companies with regulatory resources and established retail relationships while making cross-border expansion less predictable.
Consumer education remains a category-level constraint because many buyers cannot easily distinguish between product quality, legal status, intended use, and evidence boundaries. Transparent testing, clear dosage communication, and trusted professional channels can reduce hesitation, but inconsistent category practices continue to limit conversion among risk-sensitive consumers.
GMI Analyst View
We find that regulatory progress alone will not determine category expansion. The stronger commercial outcome emerges where compliance infrastructure is matched with credible consumer education and channel trust. Markets that solve both requirements are more likely to convert underlying wellness interest into sustained purchasing behavior.
CBD Nutraceuticals Market Segment Analysis
By Product
In the CBD Nutraceuticals Market, CBD oils generated USD 4.36 billion in 2025 and are projected to account for 31.0% of global market revenue by 2035. The format remains foundational because it offers flexible dosing and familiarity among established users, although its relative position is moderated by the expansion of more convenient, pre-measured alternatives.
CBD capsules & softgels are projected to reach USD 14.44 billion by 2035 and represented 22.0% of global revenue in 2025. Their conventional supplement presentation supports adoption among consumers who prioritize standardized dosing, portability, and a clinical-adjacent product experience, particularly in pharmacy-oriented channels.
CBD gummies & chews are projected to reach USD 16.21 billion by 2035 and are expected to grow at 21.8% CAGR (2026–2035). Palatable, pre-dosed formats reduce the product-specific knowledge required for trial and fit naturally with sleep and stress-support routines, making them well suited to mainstream retail and digital acquisition.
CBD tinctures generated USD 2.49 billion in 2025 and are projected to hold 16.6% of global revenue by 2035. Tinctures retain relevance for experienced consumers who value sublingual administration and adjustable intake, but their more specialized usage profile creates a narrower pathway to mass-market adoption than capsules, softgels, or gummies.
By Application
Pain Management is projected to generate USD 17.83 billion by 2035 and accounted for 35.0% of global revenue in 2025. Its scale reflects the broad base of consumers managing chronic discomfort, where repeat-use behavior and a preference for non-pharmaceutical wellness options support durable category demand.
Anxiety & Stress Reduction is projected to reach USD 17.21 billion by 2035 and represented 28.0% of global revenue in 2025. The application remains central to CBD nutraceutical positioning because consumers recognize stress relief as an established use case, creating a substantial base for products that combine clear communication with easy-to-use delivery formats.
Sleep Disorders generated USD 2.49 billion in 2025 and are expected to grow at 19.1% CAGR (2026–2035). Demand is strengthened by consumers seeking non-prescription sleep-support routines, while gummies and other pre-dosed formats create an intuitive bridge between a relaxation proposition and habitual evening consumption.
Mental Health generated USD 1.49 billion in 2025 and is forecast to expand at 21.5% CAGR (2026–2035). This segment benefits from rising willingness to address psychological wellness through supplementation, but its continued development depends on carefully bounded claims, credible advisory support, and channels that can build consumer confidence.
By Distribution Channel
Retail Stores accounted for 38.0% of global revenue in 2025 and are expected to grow at 15.0% CAGR (2026–2035). Physical stores remain important for product discovery, in-person reassurance, and cross-category shopping, particularly for consumers who want to inspect labels or seek guidance before initiating CBD use.
E-commerce is projected to hold 36.0% of global revenue by 2035 and is forecast to grow at 19.5% CAGR (2026–2035). Digital channels support subscription replenishment, product comparison, and direct access to testing information, while also giving brands stronger consumer data and a more direct relationship with repeat purchasers.
Pharmacies generated USD 3.24 billion in 2025 and are projected to account for 29.0% of global revenue by 2035. The channel is increasingly important for standardized products and pain-management positioning because pharmacist engagement can provide the professional reassurance needed by risk-conscious and first-time consumers.
GMI Analyst View
We see the segment mix shifting toward products that reduce decision friction without compromising trust. Formats that feel familiar to supplement users, paired with application-specific positioning, can widen adoption more effectively than broad, undifferentiated CBD propositions. The strategic challenge is to make accessibility and credibility reinforce each other.
CBD Nutraceuticals Market Regional Analysis
North America CBD Nutraceuticals Market Analysis
The CBD Nutraceuticals Market in North America accounted for 40.0% of global revenue in 2025 and is projected to reach USD 20.03 billion by 2035. The region combines mature direct-to-consumer activity with broad retail availability and a growing opportunity for pharmacy-oriented products as compliance expectations become more defined.
United States
The United States accounted for 87.5% of North American revenue in 2025 and is projected to reach USD 16.87 billion by 2035. Its large installed consumer base, developed e-commerce infrastructure, and expanding interest in pharmacist-supported wellness products make it the region's principal commercial center. Federal regulatory developments are particularly consequential because clearer compliance conditions can improve retailer confidence and support more formalized channel participation.
Canada
Canada generated USD 622 million in 2025 and is expected to grow at 17.6% CAGR (2026–2035). A comparatively established regulatory environment and high consumer familiarity support measured market development, while pharmacy expansion and format diversification create room for continued growth.
Europe CBD Nutraceuticals Market Analysis
Europe generated USD 3.98 billion in 2025 and is expected to grow at 17.8% CAGR (2026–2035). The CBD Nutraceuticals Market across Europe is shaped by national variation in novel-food authorization, retail access, and product-compliance requirements, producing uneven but increasingly structured commercial development.
United Kingdom
The United Kingdom generated USD 797 million in 2025 and is projected to reach USD 4.73 billion by 2035. The country's novel-food process provides a clearer route toward compliant commercialization than many European markets, supporting stronger prospects for brands able to meet authorization and product-quality requirements.
Germany
Germany accounted for 18.0% of European revenue in 2025 and is forecast to grow at 18.5% CAGR (2026–2035). A well-developed pharmacy environment and consumer familiarity with botanical supplements create favorable conditions for CBD products positioned with transparent quality and disciplined health-support messaging.
France
France generated USD 558 million in 2025 and is projected to reach USD 2.68 billion by 2035. Demand is developing despite a more restrictive commercial environment, with e-commerce and pharmacist engagement offering routes to growth as compliance pathways become more workable.
Asia Pacific CBD Nutraceuticals Market Analysis
Asia Pacific is projected to reach USD 16.85 billion by 2035 and is expected to grow at 19.9% CAGR (2026–2035). The CBD Nutraceuticals Market in Asia Pacific benefits from rising preventive-health spending, broad interest in functional supplements, and the scale available when regulatory normalization supports formal retail and pharmacy participation.
China
China generated USD 822 million in 2025 and is projected to reach USD 5.53 billion by 2035. Consumer interest in herbal and wellness products, combined with e-commerce and cross-border purchasing, provides a meaningful demand base, although the pace of domestic market development remains closely tied to regulatory progress.
India
India is projected to account for 30.9% of Asia Pacific revenue by 2035 and is expected to grow at 22.5% CAGR (2026–2035). A large consumer base, expanding urban purchasing power, and an established cultural affinity for herbal wellness products make the market strategically important as state-level regulatory development evolves.
Japan
Japan generated USD 411 million in 2025 and is projected to account for 11.7% of Asia Pacific revenue by 2035. Its mature supplement culture and high consumer spending capacity support demand, but a more constrained regulatory path limits its relative pace compared with faster-developing regional markets.
Australia
Australia accounted for 12.0% of Asia Pacific revenue in 2025 and is expected to grow at 15.0% CAGR (2026–2035). Its earlier development of a pharmacy-based pathway for low-dose CBD supports a comparatively mature commercial setting, although market expansion is tempered by the country's smaller population base.
South Korea
South Korea generated USD 219 million in 2025 and is projected to reach USD 1.30 billion by 2035. Functional wellness engagement and evolving product-classification conditions create a pathway for growth, particularly where CBD products can be positioned with clear quality assurance and supplement-category relevance.
Latin America CBD Nutraceuticals Market Analysis
Latin America generated USD 498 million in 2025 and is projected to reach USD 2.84 billion by 2035. The CBD Nutraceuticals Market in the region is being built around developing compliance frameworks, expanding pharmacy access, and rising interest in health-support products, with Brazil serving as the primary commercial anchor.
Brazil
Brazil generated USD 224 million in 2025 and is projected to reach USD 1.28 billion by 2035. Its established regulatory pathway for CBD health products has created an earlier opening for domestic development and international participation, supported by a large urban consumer base and expanding pharmacy distribution.
Mexico
Mexico accounted for 30.0% of Latin American revenue in 2025 and is expected to grow at 17.0% CAGR (2026–2035). E-commerce is especially relevant to market development because it can extend access while the commercial framework for conventional retail and pharmacy distribution continues to evolve.
Argentina
Argentina is projected to account for 12.9% of Latin American revenue by 2035 and is expected to grow at 22.0% CAGR (2026–2035). Enabling legislation and a strong tradition of integrative wellness create favorable demand conditions, although the market is developing from a smaller commercial base than Brazil or Mexico.
Middle East & Africa CBD Nutraceuticals Market Analysis
Middle East & Africa generated USD 249 million in 2025 and is projected to reach USD 1.26 billion by 2035. The CBD Nutraceuticals Market remains at an earlier stage of development across the region, where progress depends on the emergence of credible hemp-derived CBD rules, premium supplement retail, and consumer education.
UAE
The UAE accounted for 35.0% of Middle East & Africa revenue in 2025 and is expected to grow at 20.0% CAGR (2026–2035). Premium retail infrastructure, a large expatriate population, and the country's role as a regional commercial hub support its position as an early market for functional wellness products.
Saudi Arabia
Saudi Arabia generated USD 62 million in 2025 and is projected to reach USD 274 million by 2035. Demand potential is supported by a young population and growing interest in alternative wellness approaches, while market development remains dependent on the pace of formal health-supplement registration pathways.
South Africa
South Africa accounted for 20.0% of Middle East & Africa revenue in 2025 and is projected to generate USD 262 million by 2035. Its comparatively developed pharmacy and health-store network supports category access, although consumer affordability and careful regulatory compliance remain material considerations.
GMI Analyst View
We expect regional performance to diverge most sharply where regulation either enables or delays trusted distribution. Asia Pacific has the greatest structural headroom, while North America's opportunity is increasingly tied to institutionalization rather than simple category discovery. In emerging regions, credible compliance and education will determine whether latent demand becomes scalable commercial demand.
CBD Nutraceuticals Market Share & Competitive Landscape
The CBD Nutraceuticals Market share landscape remains highly fragmented, with the top five companies collectively holding approximately 1.45% of global revenue in 2025. Fragmentation reflects the coexistence of direct-to-consumer specialists, regional brands, white-label suppliers, and more established supplement companies, none of which yet exerts platform-scale influence across all major geographies and channels.
Green Roads held 0.47% of global market revenue in 2025. Its pharmacist-founded positioning and focus on broad-spectrum and CBD isolate products support differentiation among consumers and channel partners seeking a more professionally oriented product proposition. The company's ability to sustain this identity will depend on translating product credibility into repeatable pharmacy and retail relationships.
Charlotte's Web held 0.36% of global market revenue in 2025. The company has broadened its strategic focus beyond traditional CBD formats through functional product development, clinical-advisory activity, and healthcare-channel infrastructure. This positioning reflects a wider competitive shift toward brands that can demonstrate responsible use, product quality, and channel readiness.
Garden of Life (Nestlé) held 0.36% of global market revenue in 2025. Backing from a large dietary-supplement organization provides advantages in manufacturing systems, quality assurance, and mainstream distribution relationships. These capabilities can be particularly valuable as retailer and pharmacy buyers place greater weight on compliance documentation and product consistency.
MEDTERRA competes through a clinical and purity-oriented brand identity, including pharmacist-recommended positioning and third-party quality verification. CV Sciences maintains a presence through CBD oils and capsules distributed across natural, specialty, and online channels, while its public reporting offers a degree of commercial transparency that remains uncommon in the fragmented U.S. market.
Elixinol, ENDOCA, Bluebird Botanicals, Diamond CBD, Irwin Naturals, Isodiol, Medical Marijuana, and Foria Wellness represent a diverse specialty tier. Their strategies span wholesale supply, direct-to-consumer transparency, format innovation, conventional supplement retail, and premium wellness positioning. Competitive success will increasingly depend on the ability to pair differentiated consumer propositions with credible quality, compliance, and channel execution.
Recent Industry Developments
Food Standards Agency Recommends First CBD Novel Food Authorisations — September 2026
The UK Food Standards Agency recommended that ministers in England and Wales authorize the first CBD novel food applications, covering high-purity CBD isolate products submitted by Cannaray Brands, EIHA, and Chanelle McCoy CBD. The recommendation provides a meaningful signal of progress toward formal authorization and could improve commercial certainty for compliant CBD product suppliers in Great Britain [6]Food Standards Agency. "CBD novel food applications: recommendations to ministers on first authorisations." gov.uk.
Charlotte’s Web Selected as CBD Partner for Potential Medicare and Medicaid Pilot — December 2025
Charlotte’s Web announced its participation as a CBD provider in a potential Center for Medicare and Medicaid Innovation pilot program for senior oncology patients. If implemented, the initiative would connect product access, digital delivery, and outcomes-oriented healthcare infrastructure, representing a notable test of CBD’s potential role in more formal care-adjacent channels [7]Charlotte's Web Holdings. "Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program." investors.charlottesweb.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →